Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Duquesne Family Office has beefed up its healthcare holdings.
NTRA - Natera, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$319.00
DETAILS
HIGH:
$375.00
LOW:
$245.00
MEDIAN:
$335.00
CONSENSUS:
$319.00
DOWNSIDE:
5.80%
Stock News
Callan Family Office LLC Buys New Shares in Natera, Inc. $NTRA
Callan Family Office LLC bought a new position in Natera, Inc. (NASDAQ: NTRA) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 3,582 shares of the medical research company's stock, valued at approximately $972,000. Other institutional investors have also added to or reduced
Bank of Nova Scotia Purchases Shares of 44,200 Natera, Inc. $NTRA
Bank of Nova Scotia purchased a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 44,200 shares of the medical research company's stock, valued at approximately $11,998,000. Other institutional investors have also recently
14,588 Shares in Natera, Inc. $NTRA Acquired by Brandywine Managers LLC
Brandywine Managers LLC acquired a new stake in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 14,588 shares of the medical research company's stock, valued at approximately $3,960,000. Natera comprises about 2.0% of Brandywine Managers
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.
Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.
Bank of New York Mellon Corp Makes New $149.28 Million Investment in Natera, Inc. $NTRA
Bank of New York Mellon Corp acquired a new position in Natera, Inc. (NASDAQ: NTRA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 549,927 shares of the medical research company's stock, valued at approximately $149,278,000. Bank of New York Mellon
Natera, Inc. (NASDAQ:NTRA) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Natera, Inc. (NASDAQ: NTRA - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-two analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and two have
Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story?
The hedge fund legend has bet much of the family office on this one diagnostics company.
13F Season: Where Wall Street's Smart Money is Betting
Quarterly 13F disclosures offer individual investors an irreplaceable window into the playbooks of market-moving institutions.
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
Empowered Funds LLC Sells 9,708 Shares of Natera, Inc. $NTRA
Empowered Funds LLC decreased its position in shares of Natera, Inc. (NASDAQ: NTRA) by 65.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,016 shares of the medical research company's stock after selling 9,708 shares during the quarter. Empowered
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference
Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.
Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Natera, Inc. (NTRA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial circulating tumor DNA (ctDNA) dynamics as part of trea.
What to Know About This Natera Insider Transaction as Shares Surge to Record Highs
Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.
A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests
This sale was executed under a pre-arranged Rule 10b5-1 trading plan.
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.
Druckenmiller only owns one "Magnificent Seven" stock.
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status
40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shares fell to $182.65.
Natera Q2 Earnings Call Highlights
Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women's health and organ health businesses.
Price Targets
Natera price target raised to $350 from $305 at Stephens
$350.00
(was $317.25)
Stephens
Natera price target raised to $360 from $290 at Guggenheim
$360.00
(was $312.72)
Guggenheim
Natera price target raised to $355 from $310 at Morgan Stanley
$355.00
(was $323.58)
Morgan Stanley
Natera price target raised to $350 from $275 at RBC Capital
$350.00
(was $316.14)
RBC Capital
Natera price target lowered to $348 from $379 at Baird
$348.00
(was $265.38)
Catherine Ramsey Schulte
·
Robert W. Baird
Natera price target raised to $375 from $330 at Canaccord
$375.00
(was $265.38)
Kyle Mikson
·
Canaccord Genuity
Natera price target raised to $284 from $220 at Wells Fargo
$284.00
(was $265.38)
Wells Fargo
Natera price target raised to $320 from $290 at BTIG
$320.00
(was $265.38)
BTIG
Natera price target raised to $330 from $280 at Leerink
$330.00
(was $265.38)
Leerink Partners
Natera price target raised to $340 from $260 at Barclays
$340.00
(was $265.38)
Barclays
Natera price target raised to $330 from $285 at Canaccord
$330.00
(was $272.89)
Canaccord Genuity
Natera price target raised to $310 from $250 at Morgan Stanley
$310.00
(was $274.39)
Morgan Stanley
Natera price target raised to $300 from $270 at Evercore ISI
$300.00
(was $281.26)
Evercore ISI
Natera price target raised to $290 from $270 at Guggenheim
$290.00
(was $261.91)
Subbu Nambi
·
Guggenheim
Natera price target raised to $275 from $270 at BTIG
$275.00
(was $260.72)
BTIG
Natera price target lowered to $260 from $280 at Barclays
$260.00
(was $234.76)
UBS
Natera (NTRA) PT Raised to $270 at BTIGMember Login
$270.00
(was $234.76)
BTIG
RBC Capital Starts Natera (NTRA) at Outperform
$275.00
(was $219.23)
Dan Leonard
·
RBC Capital
Goldman Sachs Starts Natera (NTRA) at Neutral
$245.00
(was $222.10)
Evie Koslosky
·
Goldman Sachs
Natera price target raised to $249 from $240 at Piper Sandler
$249.00
(was $199.14)
Piper Sandler